RBC Capital Thinks Karyopharm Therapeutics’ Stock is Going to Recover

By Jason Carr

RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics (KPTIResearch Report) on April 8 and set a price target of $24.00. The company’s shares closed last Friday at $10.02, close to its 52-week low of $9.75.

According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 6.7% and a 47.2% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intra-Cellular Therapies, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Karyopharm Therapeutics is a Strong Buy with an average price target of $30.40, representing a 201.9% upside. In a report issued on March 30, H.C. Wainwright also maintained a Buy rating on the stock with a $49.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $25.98 and a one-year low of $9.75. Currently, Karyopharm Therapeutics has an average volume of 2.53M.

Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KPTI in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.